Angle Share Discussion Threads

[zeus19] 08/1/2025 07:45

https://gb.bebee.com/company/angle-plcTheres atleast 20

[markymark33] 07/1/2025 18:50

I count 8. Where you getting 28 from?

[thiopia] 07/1/2025 15:56

FAB a £4m Mkt Cap Company recently got non-dilutive funding of £6m as part of a £55m UK government Future Medicines Initiative. Is it possible AGL could secure something similar ?

[toffeeman] 07/1/2025 15:39

Website has 28 job vacancies - assume an average employment cost of £50k - that's £1.4m additional overhead at least.

Methinks that means some positive trial results on the way.

[gooosed] 07/1/2025 14:35

"constant and unstoppable growth"

"Unveiling the potential of CTCs in drug resistance mechanisms and personalized medicine"

"However, the potential of CTCs should not remain confined only to prognostic study but be extended also to clinical practice. Therefore, it is of pivotal importance to explore the clinical relevance of CTCs beyond their prognostic value, studying the emerging methods application for CTCs to use the information deriving from CTCs in the treatment of patients through precision therapy. The information provided by CTCs about genetic mutations, gene expression patterns, and biomarkers can be used to identify specific molecular targets for understanding drug resistance mechanisms and drug development, leading to personalized treatment options that can prevent metastasis and improve patient outcomes.

This Research Topic focused on the recognition methods of CTCs based on deep learning and emerging tools to investigate the genome, transcriptome, proteome, and secretome of CTCs as biomarkers."

"Conclusions
In conclusion, this Research Topic highlights the importance of exploring the clinical relevance of CTCs beyond their prognostic value. The key findings discussed herein demonstrate that the studies on liquid biopsy for its use in tumors are in constant and unstoppable growth, and the strong interest in this field of research, supported by these scientific articles, gives us hope that the data we will collect with future research on the clinical applicability of CTCs will soon be used in clinical practice."



Ps. Recruitment drive under way :

Clinical Scientist Imaging

Clinical Data Analyst Molecular

Clinical Scientist Molecular

Technical Support Scientist

Clinical Study Manager

Medical Laboratory Assistant

Head of Regulatory Affairs

Clinical Scientist I, Technology Transfer

[gooosed] 06/1/2025 10:21

To add to the above link - may be of interest to some :

"Conclusions and Relevance

In this prognostic study, the findings validate CTC count as a prognostic biomarker that improved upon existing prognostic factors and estimated vastly divergent survival outcomes regardless of subsequent lines of therapy. As such, baseline CTC count in mHSPC may serve as a valuable noninvasive biomarker to identify men likely to have poor survival who may benefit from clinical trials of intensified or novel regimens."



&

"Observations and comments
"This research emphasizes the continued emergence of CTCs in helping to determine outcomes and potentially treatment options for men with metastatic prostate cancer," said Dr. Marc Garnick, the Gorman Brothers Professor of Medicine at Harvard Medical School and Beth Israel Deaconess Medical Center, and editor in chief of the Harvard Medical School Guide to Prostate Diseases."

[dreamtwister] 05/1/2025 17:06

liquid biopsy's are being adopted.

[gooosed] 04/1/2025 12:44

Bermudashorts - your 26892, good spot!

[htrocka2] 03/1/2025 12:20

Havingthelasttoast.....why should you worry where this is headed?

[havinthelasttoast] 03/1/2025 11:37

See this dog is on its last days. Two more bad updates and raises and it’s night night.

[millwallfan] 03/1/2025 09:08

We need an ‘oh my gush’ year rather than a leak 😂

[jelenko] 03/1/2025 08:16

No news has leaked, AGL is a tight ship. January is more often than not a good month for AGL's share price.

[seball] 03/1/2025 08:07

Some news has leaked and insiders buying. Buy and Hold for news imo

[thiopia] 03/1/2025 07:45

Looks like a breakout of the medium term downtrend (albeit still need to take out the 200 day MA resistance in the 12s)


free stock charts from uk.advfn.com

[castor111] 02/1/2025 20:21

Follow the money...

[dave4545] 02/1/2025 20:00

Momentum can really drive this at times.

The price trebled from this level this time last year.

Fair chance of a 50-100%+ trade gain if it goes again

Signs were there today it might

[thiopia] 02/1/2025 19:45

free stock charts from uk.advfn.com

[yasx] 02/1/2025 16:16

Bermuda,

Thank you for highlighting that information.

[bagpuss67] 02/1/2025 16:12

Works for me!

[jelenko] 02/1/2025 15:49

fair, LOL.

[seball] 02/1/2025 15:41

100p takeover from AstraZeneca would be fair imo

[muffster] 02/1/2025 14:09

Thanks Bermuda Analyst forecasts here are for a share price of 94p to 105p. Wonder what AZ will offer as that is my expectation

[bagpuss67] 02/1/2025 14:05

Lets hope for a decent 2025 for AGL :)

[bermudashorts] 02/1/2025 14:03

New research featuring Parsortix was published yesterday. At the moment it's a preprint (awaiting peer review) so may not be the final version but worth a look. The researchers were investigating the use of genomic profiling of CTCs to predict survival in colorectal cancer patients. They found that patients with CTCs showing a high levels of genetic mutations had a poorer prognosis with reduced overall survival. Mutations in the BCL9L gene were particularly significant. They then went on to develop a gene panel of 55 of the most frequently mutated genes and found a strong correlation with survival. This is how they summarised their fingings:-

'In summary, our study demonstrates for the first time a relationship between CTC genomic diversity and overall survival in mCRC, underscoring the potential of genomic profiling of CTCs as a novel prognostic tool in mCRC and highlighting the need for further research into the clinical applications of CTC genomics, which could ultimately improve personalized treatment strategies for cancer patients.'

Whilst this publication isn't going to make any short term difference to Angle's fortunes, it is yet further evidence that the Parsortix system has and is making a real contribution to our understanding of cancer at a molecular level. There appears to be a growing awareness and acceptance of the value of CTC analysis. We can only hope that with time CTC liquid biopsies will be routinely used in the clinical setting and that Angle are able to capitalise on that.